Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company, on June 17,2022 . We request you to take the same on record and acknowledge the receipt. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agents (RTA), KFin Technologies Limited on June 03,2022, regarding the loss /misplacement of share certificate(s). We request you to take the same on record and acknowledge receipt Procter & Gamble Health Ltd - 500126 - Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividend Income From Procter & Gamble Health Limited ('The Company')
In accordance with the provisions of the Income Tax Act, 1961 as amended by and read with the provisions of the Indian Finance Act, 2020, dividend declared and paid by the Company after April 1, 2020, is taxable in the hands of shareholders and the Company is required to deduct the tax at source ('TDS'). Shareholders holding shares in dematerialized mode, are requested to update their records such as tax residential status, permanent account number (PAN) and register their email addresses, mobile numbers and other details with their relevant depositories through their depository participants. shareholders holding shares in physical mode are requested to furnish details to the Company's registrar and share transfer agent KFin Technologies Limited, to determine the appropriate TDS rate (if any). Q4FY22 Quarterly Result Announced for Procter & Gamble Health Ltd.
Procter & Gamble Health declares Q4FY22 result: Procter & Gamble Health announces third quarter results showing 14% growth in net profits. Sales of Rs 262 crores and PAT of Rs 51.2 Crores for quarter ended March 31, 2022 Sales for the quarter up by 23% The Company has delivered total sales of Rs 262 crores for the quarter ended March 31, 2022 vs Rs 214 crores, up by 23% vs year ago. The Profit After Tax (PAT) was Rs 51.2 crores, up by 224% vs year ago. Increase in PAT is driven by higher sales and lower marketing and depreciation charge vs same period last year. Sales for the nine-month period ending March 31, 2022, were Rs 803 crores, vs Rs 710 crores up 13% vs a year ago. PAT for nine-month period is Rs 151 crore Vs Rs 143 crore a year ago, despite high inflationary pressures. Mr. Milind Thatte, Managing Director, P&G; Health India, said, “We have been able to register consistent growth in revenue and earnings in recent quarters. Our strong portfolio of products that address the increasing demand for daily supplementation and a renewed focus on expanded reach and improved productivity continue to form the pillars of our strategy. We will leverage our strengths in medico-marketing, technology and distribution, in order to better serve the consumers and customers who count on us.” “We continue our efforts in promoting consumer education, raising awareness around women’s health and overall health and wellness. This year, we launched ‘Women in Healthcare’ summit as a platform to encourage more women to join the healthcare and pharma sectors. We continue to strengthen and expand our projects under SEHAT, our CSR program that aims at contributing to building a healthier India. Recently, we partnered with Apnalaya, to extend our support to the urban poor and provide care to underprivileged pregnant women, new mothers and newborns,” he added. Result PDF Procter & Gamble Health Ltd - 500126 - Corporate Action-Board approves Dividend
We are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2021-22 of Rs. 41 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before May 31, 2022. As informed earlier in our letter dated April 28, 2022, record date for the purpose of eligibility for payment of said Interim Dividend shall be May 13,2022. Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended March 31,2022 And Interim Dividend For The Financial Year 2021-22
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 6:00 p.m. and ended at 7: 20 p.m.), the Unaudited Financial Results for the quarter ended March 31,2022 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2022; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2022 furnished by Statutory Auditors of the Company. Procter & Gamble Health Ltd - 500126 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended March 31,2022 And Interim Dividend For The Financial Year 2021-22
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 6:00 p.m. and ended at 7: 20 p.m.), the Unaudited Financial Results for the quarter ended March 31,2022 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2022; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2022 furnished by Statutory Auditors of the Company Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2021-22 of Rs. 41 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before May 31, 2022. Procter & Gamble Health Ltd - 500126 - Record Date For Payment Of The Interim Dividend, If Declared At The Board Meeting
We refer to our letter dated March 30, 2022, informing that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 5, 2022, to consider and approve Unaudited Financial Results for the quarter ended March 31, 2022. We would like to further inform you that the Board at the said meeting, would also consider declaration of interim dividend for the Financial Year 2021-22. The record date for payment of the Interim dividend, if declared at the Board meeting, will be Friday, May 13, 2022. Kindly take the same on record. Procter & Gamble Health Ltd - 500126 - Update on board meeting
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 ,inter alia, to consider and approve We refer to our letter dated March 30, 2022, informing that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 5, 2022, to consider and approve Unaudited Financial Results for the quarter ended March 31, 2022. We would like to further inform you that the Board at the said meeting, would also consider declaration of interim dividend for the Financial Year 2021-22. The record date for payment of the Interim dividend, if declared at the Board meeting, will be Friday, May 13, 2022. Kindly take the same on record. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company, on April 20,2022. We request you to take the same on record and acknowledge the receipt.